AEON BIOPHARMA INC

AEONNYSE AMERICAN

🏆 #4411 by market capUS Equity

$0.27▲ $0.00 (+0.33%)

Live

1h—

24h▲ 0.3%

7d▼ 7.2%

14d▲ 8.5%

30d▼ 13.7%

1y▼ 56.9%

🏦Market Cap

$10M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $0.27 – $0.28
52-Week Range: $0.22 – $1.45
Volume: $2.79B
Avg Volume: $2.30B
Shares Outstanding: 37.2M
Next Earnings: Oct 15, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $413,098
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.16
Dividend Yield: —

Why Investors Own AEON

✓High-growth profile — revenue up +57.0% YoY with expanding US Equity exposure.
✓Healthy economics — 33% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +57.7% YoY

Gross Margin (TTM)

32.9%▲ +0.3% YoY

Operating Income (TTM)

$498,495▲ +57.7% YoY

Free Cash Flow (TTM)

$303,582▲ +57.7% YoY

About AEON BIOPHARMA INC

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

🦦